We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

First- and Second-Generation Antipsychotics: Learning From CUtLASS and CATIE

Rajiv Tandon, MD; William T. Carpenter, MD; John M. Davis, MD
Arch Gen Psychiatry. 2007;64(8):977-978. doi:10.1001/archpsyc.64.8.977.
Text Size: A A A
Published online


We sought to understand how findings of the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS band 1)1 and their comparison with those from phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study in schizophrenia2,3 clarify issues raised in our 2005 American Psychiatric Association annual meeting debate “Second-Generation Antipsychotics (SGAs) Are Uniformly Superior in Efficacy and Safety to First-Generation Antipsychotics (FGAs).”4 Applying the primary effectiveness metric used in CATIE to CUtLASS band 1 findings, we noted that in contrast to 60 of 118 patients (51%) assigned to receive an FGA who continually took an FGA through the 1-year study, 70 of 109 patients (64%) assigned to receive an SGA did so (χ21 = 4.14; P < .05). In CUtLASS band 1, SGAs were found to be more effective than FGAs in terms of all-cause discontinuation. Despite this apparent SGA advantage in a nonblinded aspect of that study, results of both CATIE and CUtLASS band 1 indicate that FGAs are as effective as SGAs. How does one reconcile this observation with previous findings suggesting that SGAs are more effective than FGAs?


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

12 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.